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Abstract: Chronic hepatitis B virus infection (CHB) caused by the hepatitis B virus (HBV) is one of
the most common viral infections in the world. Reactivation of HBV infection is a life-threatening
condition observed in patients with CHB receiving chemotherapy or other medications. Although
HBV reactivation is commonly attributed to immune suppression, other factors have long been
suspected to play a role, including intracellular signaling activated in response to DNA damage.
We investigated the effects of DNA-damaging factors (doxorubicin and hydrogen peroxide) on HBV
reactivation/replication and the consequent DNA-damage response. Dose-dependent activation
of HBV replication was observed in response to doxorubicin and hydrogen peroxide which was
associated with a marked elevation in the mRNA levels of ataxia-telangiectasia mutated (ATM) and
ATM- and RAD3-related (ATR) kinases. Downregulation of ATM or ATR expression by shRNAs
substantially reduced the levels of HBV RNAs and DNA. In contrast, transcriptional activation of
ATM or ATR using CRISPRa significantly increased HBV replication. We conclude that ATM and
ATR are essential for HBV replication. Furthermore, DNA damage leading to the activation of ATM
and ATR transcription, results in the reactivation of HBV replication.
Keywords: HBV reactivation; replication; DNA damage; ATM; ATR; phosphorylated H2AX; yH2AX;
shRNA; CRISPR/Cas9; CRISPRa; dCas9
1. Introduction
Hepatitis B virus (HBV) causes acute or chronic hepatitis B virus infection (CHB) [1]. HBV infection
affects over 2 billion people worldwide; around 250 million people are chronically infected and 1 million
die annually due to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma [2]. Modern
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antivirals effectively inhibit virus replication and substantially decrease the risks of unfavorable HBV
infection outcomes [3]. Comorbidities in patients with CHB often require additional interventions,
such as cancer chemotherapy, immunosuppressive therapies after liver transplantation, treatment of
viral hepatitis C in HBV-HCV-co-infected individuals which may trigger an abrupt reactivation of
HBV infection [4,5]. In patients undergoing chemotherapy and therapy with immunosuppressive
drugs, treatment may result in lethal HBV reactivation [6–8]. This turns HBV reactivation into a serious
clinical problem posing a major threat to global public health.
Therapies that can result in HBV reactivation can be divided into several major groups based
on their mode of action, namely: DNA damage, TNF-α inhibition, B-cell depletion, histone
deacetylase inhibition, chemokine or integrin inhibition, kinase inhibition, and proteasome inhibition [5].
The precise mechanisms of HBV reactivation upon administration of different agents remain largely
unknown, but has been linked either to the impairment of immune responses (TNF-α inhibitors,
B-cell depleting agents, chemokine and integrin inhibitors, kinase inhibitors, proteasome inhibitors)
or activation of transcription of HBV covalently closed circular DNA (cccDNA) (histone deacetylase
inhibitors) [5]. Several lines of evidence indicate that HBV reactivation may be related to oxidative stress,
DNA damage/DNA damage response and interconnected alterations in the intracellular signaling and
cell cycle progression in the infected cells [9–15].
The DNA damage response (DDR) involves activation of a series of kinases, including the
phosphatidyl inositol 3-kinase-like kinases (PIKKs), ataxia-telangiectasia mutated (ATM), ATM-
and RAD3-related (ATR), and catalytic subunit of DNA-dependent protein kinase (DNA-PKc) [16].
Phosphorylation of PIKK target proteins results in the formation of phosphorylated H2AX foci or
yH2AX; foci of p53-binding protein (53BP1, one of the key proteins of DNA double-stranded break
[DSB] repair); phosphorylated ATM; and accumulation of p53 in the nucleus, all indicative of DNA
damage [16]. Activated ATM and ATR phosphorylates their downstream substrates Chk2 and Chk1,
respectively [17], which in turn affects different biochemical pathways of the cell, including cell cycling
and gene transcription [18]. DDR includes sensing, initiation, amplification, and implementation of
cellular responses to DNA damage, ultimately leading to either the repair of damaged DNA, or cell
senescence and death [19].
Viruses require DDR to effectively replicate in the infected cells [20]. They may recruit ATM, ATR,
and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and their interacting partners, as
well as other DDR proteins, including MRE11A and RAD51 [20]. DDR has long since been recognized
as an important player in HBV transcription and replication [21]. We and others have previously
demonstrated that the livers of patients with CHB and with HBV/hepatitis D virus co-infection harbor
yH2AX foci [22,23], a reliable marker of activated DDR [24]. In vitro studies demonstrated that HBV
infection activates DDR, resulting in increased levels of ATR and phosphorylated checkpoint kinase 1
(Chk1) [25]. Knocking down ATR decreases HBV transcription and replication, mainly due to reduced
Chk1 phosphorylation. Additionally, DDR has been reported to enhance activity of HBV cccDNA
promoters both in vitro and in vivo [10]. Importantly, cytoplasmic HBV X (HBx) protein, a key factor of
HBV cccDNA transcription, induces endoplasmic reticulum (ER) stress and DNA damage by activating
the ATM-checkpoint kinase 2 (Chk2) signaling cascade, resulting in increased HBV transcription and
replication [26]. On the contrary, inhibitors of ATM and ATR kinases (caffeine and theophylline) or of
Chk1 (UCN01) suppress HBV replication and HBV-related pathogenesis [25]. These findings suggest
an important role of DDR signaling in the natural HBV life cycle. In line with this, chemotherapeutic
agents which induce DNA damage and activate DDR, such as doxorubicin [9] and cisplatin [13] which
trigger p53, p21, ATR, and Chk1 signaling, may trigger reactivation of HBV infection.
Despite this accumulated evidence, the precise mechanisms involved in HBV reactivation upon
DNA damage, as well as the roles of individual DDR components in the HBV replication, remain
largely unknown.
To address the role of DDR in HBV reactivation and replication, we analyzed HBV replication
in cells after DNA damage induced by doxorubicin, a DNA-damaging drug used to treat various
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malignancies [27], or hydrogen peroxide (H2O2) [28]. We show that doxorubicin and H2O2 cause severe
DNA damage, which, in turn, upregulates the transcription of ATM and ATR and stimulates HBV
replication. We have transiently knocked down ATM and ATR with respective shRNA, and found that
suppression of ATM and ATR transcription suppressed HBV replication. Conversely, transcriptional
activation of ATM or ATR using the CRISPRa technique [29] potentiates HBV replication, mimicking
the effects of DNA-damaging agents. These findings indicate that ATM and ATR play an important
role in the reactivation of HBV replication switching it upon DNA damage. Further studies of the basic
mechanisms behind HBV reactivation are of crucial importance for the correct management of patients
with CHB with respect to the choice of medical interventions (transplantation, chemotherapy or other),
and also for the design and application of new antiviral drugs.
2. Materials and Methods
2.1. Cell Culture
Human HEK-293T (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), HepG2,
HepG2-1.1merHBV, and HepG2-1.5merHBV (kindly provided by Dieter Glebe, University of
Giessen, Germany) cell lines were maintained in complete DMEM with 10% FBS (Thermo Fisher
Scientific, Waltham, MA, USA), 2 µM l-glutamine (Sigma Aldrich, St. Louis, MO, USA), and 1%
penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA). HepG2-1.1merHBV is an inducible cell
line with a 1.1-mer HBV genome regulated by a tet-on CMV promoter, HepG2-1.5merHBV produces
HBV constitutively; both cell lines have been described previously [30,31]. HepG2-1.1merHBV cells
were supplemented with 100 ng/mL doxycycline (Sigma Aldrich, St. Louis, MO, USA) to activate
HBV replication. Doxycycline was removed after 24 h of incubation, and cells were washed twice
with PBS and cultured in complete medium before harvest. HEK-293T cells were transfected with
HBV-encoding plasmid containing 1.1merHBV under CMV promoter [32] using polyethylenimine
(Sigma Aldrich, St. Louis, MO, USA). Recombinant cccDNA was produced using minicircle technology
(System Biosciences, Palo Alto, CA, USA) in a ZYCY10P3S2T E. coli bacterial recombination system
generating circular HBV cccDNA genome with elimination of DNA plasmid backbone, and used to
transfect HepG2 cells as was described previously [33].
2.2. Chemicals
Doxorubicin (Sigma Aldrich, St. Louis, MO, USA) was dissolved in DMSO (Sigma Aldrich,
St. Louis, MO, USA) and aliquots were stored at −80 ◦C. H2O2 (3% solution in water) was stored at
room temperature.
HepG2-1.1MerHBV, activated HepG2-1.1merHBV, and HepG2 cells transfected with
HBV-encoding plasmid were treated with doxorubicin or H2O2 for 1 h at concentrations provided
in Table 1. Next, cells were washed twice with PBS and either immediately harvested for analysis,
or incubated for an additional 24 h.
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Table 1. Concentrations of doxorubicin and H2O2 used in the study.















2.3. Isolation of Nucleic Acids
At harvest, the culture medium was discarded, and cells were washed twice with PBS and lysed
in AmpliSens Riboprep lysis buffer (AmpliSens Biotechnologies, Moscow, Russia). Nucleic acids were
isolated using the AmpliSens Riboprep kit (AmpliSens Biotechnologies, Moscow, Russia) according
to the manufacturer’s instructions. RNA was isolated as described previously. Briefly, nucleic acids
were treated with RNase-free DNase I (New England Biolabs, Ipswich, MA, USA) for 30 min at 37 ◦C,
purified using the AmpliSens Riboprep kit, and reverse-transcribed using AmpliSens Reverta-FL
(AmpliSens Biotechnologies, Moscow, Russia). HBV cccDNA was isolated via the HIRT procedure as
described by Cai et al. [34], followed by treatment with plasmid-safe ATP-dependent DNase (Epicentre,
Illumina Inc., Madison, WI, USA) for 12 h at 37 ◦C and inactivating the enzyme at 72 ◦C for 15 min.
Secreted HBV DNA was analyzed in a cell culture supernatant; viral DNA was isolated using the
AmpliSens Riboprep kit (AmpliSens Biotechnologies, Moscow, Russia) according to manufacturer’s
instructions and PCR-quantified with specific primers and probes.
2.4. PCR Analysis
A real-time quantitative polymerase chain reaction (qPCR) was performed using fluorescent
probes TaqMan or SYBRGreen dye (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA).
PCR targeting viral pregenomic RNA (pgRNA) amplified pre-core 3.5 kb and pregenomic 3.5 kb
HBV transcripts, surface mRNA (S-RNA) detecting both 3.5 kb transcripts, 2.4 kb and 2.1 kb HBV
RNAs and ATM, ATR, DNA-PK, MRE11a, and RAD51 mRNAs were assessed in relation to the mRNA
of the GAPDH reference gene. Levels of the total intracellular and secreted HBV DNA and cccDNA
were normalized to the content of β-globin genomic DNA. Specific sets of primers and probes are
presented in Table 2. Relative expression levels were calculated via the ∆∆Ct method.
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2.5. Knockdown of DDR Factors
The human U6 promoter amplified by PCR from pLX-sgRNA (AddGene plasmid
#60662) and shRNA-encoding oligonucleotides were cloned into pGEM-T Easy (Promega,
Madison, WI, USA). ShRNA targets were (1) ATM: 5′-TAGTGTTAGTGATGCAAACGA-3′;
(2) ATR: 5′-TACTGACCAATTGAAACTCTA-3′; and (3) scrambled control:
5′-CCTAAGGTTAAGTCGCCCTCG-3′. The efficacy of shRNA knockdowns and their effects
on HBV were initially tested in HEK-293T cells co-transfected with pGEM-T Easy carrying
shRNA-encoding oligonucleotides and plasmid encoding HBV by polyethylenimine. Transfection
of shRNAs into HepG2-1.1merHBV cells was performed using Lipofectamine 3000 (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Cells were transfected,
washed with PBS twice 2 days post transfection (pt), and harvested 5 days pt.
2.6. ATM and ATR Overexpression
A CRISPR activation tool (dCas9-p300) was used to transcriptionally activate ATM and
ATR. For this, sgRNAs targeting corresponding genes were designed in the CHOPCHOP sgRNA
designing tool. The following sgRNAs target sequences 5′-ACAGTTCCGAAGGCGAACGGG-3′
and 5′-CGTGCGTCGGTCAAGTTTCC-3′ were used for ATM and ATR activation, correspondingly.
The dCas9-p300mut protein with inactivated p300 activity (Addgene #61358) was expressed in
cells together with the non-targeting sgRNA 5′-GGGGCCACTAGGGACAGGAT-3′ as a mock
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control. PCR-products encoding sgRNA under the control of the U6-promoter were synthesized
as described previously using a 2-step mutagenic PCR with a Q5 high-fidelity polymerase and
purified using the Qiagen gel extraction kit (QIAGEN, Hilden, Germany) [31]. HepG2 cells were
transfected using Lipofectamine 3000 with a mix containing (1) recombinant cccDNA synthesized using
minicircle technology (System Biosciences, Palo Alto, CA, USA); (2) a plasmid encoding dCas9p300
(pcDNA-dCas9-p300 Core; Addgene #61357); and (3) a PCR product encoding gRNA. Cells were
incubated for 72 h and used for analysis of ATM and ATR expression by qPCR as described in
Section 2.4.
2.7. Immunocytochemistry
HepG2-1.1mer cells were seeded on glass coverslips and fixed in 4% paraformaldehyde for 10 min.
Next, the coverslips were washed 3 times in Tris-HCl (50 mM, pH 8.0), incubated for 30 min with
a blocking buffer (0.02% of Triton X-100, 10% horse serum, and 150 mM NaCl in Tris-HCl, 50 mM,
pH 8.0), and incubated with primary mouse monoclonal anti-yH2AX antibodies (ab26350) and rabbit
polyclonal anti-53BP1 (ab175933, Abcam, Cambridge, UK) antibodies at room temperature for 1 h.
The cells were washed 3 times for 5 min in a washing buffer (0.02% of Triton X-100 and 200 mM NaCl
in Tris-HCl, 50 mM, pH 8.0), then incubated with secondary Alexa Fluor 488 goat anti-rabbit IgG
antibodies (ab205718, Abcam, Cambridge, UK), Alexa Fluor 594 goat anti-mouse antibodies (ab150116,
Abcam, Cambridge, UK), and Hoechst33342 (to visualize the nucleus; 1/10,000; ab228551, Abcam,
Cambridge, UK) at room temperature for 1 h. The coverslips were washed 3 times for 5 min in a
washing buffer and mounted with a Fluoroshield reagent (Abcam, Cambridge, UK). Images were
captured using a Leica DMI6000 microscope with 100× immersion objectives. yH2AX and 53BP1 foci
were counted visually or using ImageJ (NIH, Bethesda, MD, USA). Foci were quantified for at least
200 cells in each experimental group. The results are presented as a mean number of foci per cell in
randomly selected areas from three independent experiments (each dot corresponds to a mean number
of foci in a selected area). The research was done using the equipment of the Core Centrum of Institute
of Developmental Biology, RAS (Moscow, Russia).
2.8. Quantification of HBsAg
Cell-conditioned media were harvested and filtered through 0.2 µm filters (Corning Inc., New York,
NY, USA) to remove cell debris. An HBV surface antigen (HBsAg) analysis in culture medium was
performed using the Abbott Architect HBsAg kit (Abbott Laboratories, Abbott Park, IL, USA).
2.9. Statistical Analysis
Values were expressed as means ± standard deviation (SD) of triplicate experiments in the
GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). Students’ t-test or one-way
ANOVA with Tukey’s HSD post hoc test were used to compare variables and calculate p-values to
determine statistically significant differences in means.
3. Results
3.1. DNA Damage Promotes HBV Replication
Treating HepG2-1.1merHBV cells with either doxorubicin or H2O2 (according to Figure S1) rapidly
increased HBV transcription and replication (Figure 1A,B). HBV transcription increased 15–20-fold
after doxorubicin treatment and over 100–300-fold after H2O2 treatment. HBV transcription was
accompanied by increase in the levels of intracellular and secreted HBV DNA and HBsAg (Figure 1A,B).
Levels of HBV intermediates increased as early as 1 h post treatment and remained elevated 24 h after
removal of the chemicals.
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Figure 1. Upregulation of HBV replication by DNA-damaging agents. Alterations in HBV
intermediates (pgRNA, S-RNA, intracellular HBV DNA, secreted HBV DNA and secreted HBsAg)
upon (A) doxorubicin and (B) H2O2 treatment in HepG2-1.1merHBV cells. Data are relative to
mock-treated control. Effects of increasing doses of (C) doxorubicin and (D) H2O2 on pgRNA levels in
HepG2-1.1merHBV cells (1.1) and HepG2-1.5merHBV cells (1.5). X-axis represents different doses of
doxorubicin and H2O2 as specified in Table 1. The results were reproduced in at least 3 independent
experiments. Asterisks indicate statistically significant differences in means compared to control.
* p < 0.05, + p < 0.01, # p < 0.001, ˆ p < 0.0001.
Next, we studied the effects of different doses of doxorubicin and H2O2 on the levels of HBV
pgRNA in HBV-replicating cell lines HepG2-1.1merHBV and HepG2-1.5merHBV (Figure 1C,D).
The highest dose of doxorubici tested (0.5 µM, Table 1) induced 20- to 100-fold upregulation of HBV
transcription in both cell lines (Figu 1C). H2O2 concentrations as low as 2–4 mM increased HBV
pgRNA levels up to 8000-fold compared to untreated cells (Figure 1D). However, in HepG2-1.1merHBV
cells, application of H2O2 in concentrations higher than 7 mM led to a decline in the levels of HBV
pgRNA (Figure 1D).
Doxorubicin and H2O2 induce DNA damage and DDR leads to the formation of yH2AX and 53BP1
foci [24]. We followed DDR signaling in the HepG2-1.1merHBV cell line treated with doxorubicin and
H2O2 by registering the formation of yH2AX and 53BP1 using immunocytochemistry (ICC). For this,
cells were treated with doxorubicin and H2O2 for 1 h and analyzed by ICC immediately or 24 h
post treatment. Treating cells with doxorubicin and H2O2 inflicted severe damage of cellular DNA
as indicated by generation of multiple yH2AX and 53BP1 foci (Figure 2A–C). Doxorubicin induced
formation of multiple yH2AX and 53BP1 foci already 1 h pt; the mean number of both yH2AX and
53BP1 foci increased 24 h pt (Figure 2B). The yH2AX and 53BP1 foci were co-localized (Figure 2D,E).
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The latter is an accepted marker of the induction of double-stranded DNA breaks (DSBs) corroborating
earlier findings [24]. In contrast to doxorubicin, H2O2 induced the formation of multiple, distinct
yH2AX, but few 53BP1 foci (Figure 2A–C) which were not co-localized (Figure 2D,E). These data
indicated that H2O2 mostly caused single-stranded DNA breaks (SSBs) (Figure 2D,E). Removing H2O2
resulted in the disappearance of a significant portion of both yH2AX and 53BP1 foci already 24 h pt
indicating DNA repair.Viruses 2019, 11, x FOR PEER REVIEW 8 of 17 
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Figure 2. Study of DDR in response to doxorubicin and H2O2 treatment in HBV replication model.
(A) Detection by immunofluorescence of the formation of 53BP1 (green) and yH2AX (red) foci 1 h
and 24 h after treatment with doxorubicin (dox) or H2O2. Cell nuclei were counterstained with
Hoechst33342 dye (blue). Quantitative analysis of (B) 53BP1 and (C) yH2AX foci, (D) the mean number
of all co-localized 53BP1/yH2AX foci per cell, and (E) percentage of co-localized 53BP1/yH2AX foci
calculated as the ratio of o-localized foc t the total number of both types of foci. Expression of DDR
factors 1 h and 24 h post (F) doxorubicin and (G) H2O2 treatments. Asterisks indicate statistically
significant differences in means compared to control. * p < 0.05, + p < 0.01, # p < 0.001, ˆ p < 0.0001.
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Formation of yH2AX and 53BP1 foci occurs shortly after DNA damage and is associated with the
activity of PIKKs, namely ATM, ATR, and DNA-PKcs [16]. Using semi-quantitative PCR, we monitored
the transcription of ATM, ATR, and DNA-PKcs together with RAD51 (a DDR factor) [36] and a factor
involved in recognizing DNA damage MRE11A [37]. We found that treating cells with doxorubicin and
H2O2 resulted in the significant upregulation of the levels of ATM and ATR mRNA, while transcription
of other DDR factors remained basically unaltered. Doxorubicin and H2O2 induced over 10-fold
upregulation of transcription of ATM and ATR, in case of H2O2 partially decreasing the day after the
treatment (Figure 2F,G).
Collectively, these results demonstrated that DNA damage caused by doxorubicin and H2O2
(doxorubicin inducing DSBs and H2O2, SSBs) leads to the upregulation of HBV transcription through a
mechanism associated with the upregulation of ATM and ATR transcription.
3.2. The Role of ATM and ATR in HBV Replication
To determine the role of individual DDR factors in HBV replication, we silenced the expression of
ATM and ATR with shRNA (see experimental scheme in Figure S2). Initially, shRNAs were tested in
HEK-293T cells transiently co-transfected with shRNA and an HBV-expressing plasmid. HEK-293T
cells express SV40 large T antigen (SV40LT) which may mask DDR [21], still, they present a useful test
system for primary assessment of the effects of shRNAs on HBV replication. ShRNA against ATM
(shATM) downregulated the expression levels of ATM by 20% (Figure 3A), whereas shRNA against
ATR (shATR) completely abolished ATR transcription (Figure 3B). Interestingly, partial knockdown of
ATM transcription reduced HBV pgRNA by over 40% (Figure 3C) and S-RNA by 10% (Figure 3D),
while abolishment of transcription of ATR reduced it by ~50–60% (Figure 3E,F).
Next, we analyzed the effects of ATM and ATR knockdowns in the HepG2-1.1merHBV cell
line. In this cell line, the transfection of shATM or shATR reduced target gene transcription by ~80%
(Figure 4A,B). Knocking down ATM also slightly decreased the levels of transcription of ATR and
MRE11A (Figure 4A), whereas knocking down ATR significantly decreased the expression of ATM,
DNA-PKcs, and RAD51 mRNAs (Figure 4B; compared to scrambled control). Both shATM and shATR
reduced the levels of HBV pgRNA (Figure 4C), HBV S-RNA (Figure 4D), intracellular HBV DNA
(Figure 4E) and secreted HBV DNA (Figure 4D). ShATR also reduced the intracellular levels of HBV
DNA, secreted HBV DNA and pgRNA by 50–85%. Similarly, shATM reduced intracellular and secreted
HBV DNA levels by ~80% and pgRNA levels by ~50%. Effects of shRNAs on S-RNA expression were
less pronounced.
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Figure 4. Suppression of HBV replication by ATM and ATR knockdown. Alterations in the transcription
of DDR factors in HepG2-1.1merHBV cells transfected with (A) shRNA against ATM and (B) shRNA
against ATR. Knocking down ATM (shATM) and ATR (shATR) reduces (C) HBV pgRNA, (D) HBV
S-RNA, (E) intracellular HBV DNA levels and (F) secreted HBV DNA levels. The results were
reproduced in at least 3 independent experiments. Asterisks indicate statistically significant differences
in means compared to control. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
These data indicate that ATM and ATR play important roles in HBV replication in vitro.
3.3. Transcriptional Activation of ATM and ATR Promotes HBV Replication
Since the elevation of ATM and ATR expression by DNA damage appears to be important for
HBV replication, we aimed to find whether transcriptional activation of ATM and ATR is sufficient to
promote HBV replication (see experimental scheme in Figure S3).
In a dCas9-p300 variant of CRISPRa technology, a catalytically inactive Cas9 (dead Cas9; dCas9)
linked to a strong activator of transcription p300 (catalytic subunit of p300 acetyltransferase) adds
Viruses 2019, 11, 997 12 of 17
marks of active chromatin to the regulatory regions of genes and turns on gene transcription [29].
We designed sgRNAs targeting dCas9-p300 protein regulatory elements of ATM and ATR genes.
Transfection of CRISPRa into HepG2 cells enhanced ATM levels >600-fold and ATR levels >4-fold
compared to a mock-treated control (Figure 5A). In HepG2 cells co-transfected with CRISPRa and HBV
recombinant cccDNA, CRISPRa-mediated activation of ATM or ATR transcription greatly induced
HBV replication. Overexpression of ATM resulted in a 40–140-fold increase in HBV transcription
(Figure 5B), ~4-fold increase in intracellular HBV DNA levels (Figure 5C) and ~2-fold increase in the
levels of secreted HBV DNA (Figure 5D). Overexpression of ATR was also associated with increased
HBV replication, although to a lesser extent than the overexpression of ATM. It led to a ~6-fold
increase in HBV transcription (Figure 5B), ~4-fold increase in intracellular HBV DNA (Figure 5C) and
secreted HBV DNA levels (Figure 5D). Experiments with shRNAs demonstrated that ATR affects HBV
replication more potently than ATM. Here, a smaller increase of HBV replication due to transcriptional
activation of ATR compared to ATM could have been due to the lower efficacy of the former.
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4. Discussion
Earlier studies demonstrated that replication of HBV in human cells results in DNA
damage inflicted by several independent but overlapping mechanisms [38–40]. Thirty years ago
Capovilla A et al., demonstrated that HBV X-protein binds to damaged DNA and sensitizes liver cells
to ultraviolet irradiation [41]. Further studies revealed that it interferes with the repair of cellular DNA
by inhibiting the repair of nucleotide excisions [42,43]. DDR pathways were apparently exploited by
HBV for replication and reactivation [14,20,44]. The key kinases activated in response to DNA damage
are ATM and ATR [16]. Zhao F et al. had shown that HBV infection triggers DDR ATR signaling,
while the downregulation of ATR expression reduces HBV replication [25]. In spite of this finding,
the actual roles of ATM, ATR, and other DDR factors in HBV replication and reactivation remain
largely unknown.
Doxorubicin and H2O2 induce DNA damage. The severity of the overall DNA damage they
induce is similar, as reflected in our study by the close total number of yH2AX and 53BP1 foci generated
in cells after each of the treatments (Figure 2A–E). Here, we have shown that both treatments strongly
upregulate the transcription of ATM and ATR, while relative transcription levels of other DDR factors,
such as DNA-PKcs, MRE11A, or RAD51, remain basically unaffected. Doxorubicin and H2O2 cause
DNA damage of different types. Doxorubicin induces DNA DSBs characterized by co-localized yH2AX
and 53BP1 foci which trigger ATM signaling [45]. H2O2 rarely induces DSBs, but generates numerous
DNA SSBs characterized by multiple yH2AX and rare 53BP1 foci, which trigger ATR signaling [45]
(Figure 2A–E). Both types of DNA damage, by doxorubicin and H2O2, significantly elevated HBV
replication. However, SSBs caused by H2O2 activated ATM and ATR transcription more efficiently
and resulted in higher levels of HBV intermediates than DSBs induced by doxorubicin. These results
strengthen the role of DNA damage response and ATM and ATR signaling in HBV reactivation.
Kim et al. had shown that HBx of HBV induces yH2AX formation and activates ATM signaling and
associated these findings with HBV pathogenesis [26]; the actual effects of ATM on HBV replication were
not evaluated. Here, in in vitro systems (HepG2, HEK-293T, HepG2-1.1merHBV, HepG2-1.5merHBV)
we have shown that the downregulation of transcription of ATR and ATM by shRNA reduced HBV
transcription, and intracellular and secreted HBV DNA levels by 50–80%, confirming the role of ATM
and ATR signaling in HBV replication. The effects on HBV replication of ATR knockdown were
more pronounced than of ATM, which corroborated the findings of Zhao et al. [25]. To dissect the
actual role of ATM and ATR in the HBV life cycle, we activated the transcription of both kinases
by CRISPRa technique. Transcriptional activation of ATM or ATR markedly increased the levels
of HBV pgRNA, HBV S-RNA, intracellular and secreted HBV DNA, confirming their role in HBV
replication/reactivation, namely in enhancing HBV transcription and replication upon DNA damage.
Unfortunately, we could not compare the potency of HBV reactivation by ATM and ATR due to the
difference in the efficacy of ATM and ATR transcriptional activation by CRISPRa.
DDR is a specific and hierarchical network that includes cell cycle checkpoints, DNA repair,
DNA-damage tolerance and alterations in cell metabolism [46]. Here, we modelled HBV replication
in the transformed cells (HEK293T, HepG2, HepG2-1.1merHBV, HepG2-1.5merHBV), in which these
mechanisms could malfunction [47]. In this respect, they may not adequately represent the primary
hepatocytes. However, the triggering of HBV replication in such cells by DNA damage and DDR
signaling indicates that in the liver such cells can serve as a depo for active viral production. The actuality
of the DNA damage mechanism of HBV (re)activation for the cells with the intact DDR would constitute
the subject of a separate study, which would require a rigorous analysis of the interactions between
DNA-damage, ATM/ATR, and HBV in physiologically relevant conditions.
Previous large-scale studies demonstrated that ATM and ATR kinases phosphorylate hundreds of
substrates and initiate widespread cell responses [18]. Following DNA damage, ATM and ATR rapidly
reprogram transcriptional and post-transcriptional profiles of the affected cells [48,49]. There is evidence
that ATM/ATR may be involved in epigenome remodeling (HDAC1/4, EZH2), cell cycle checkpoint
signaling, regulating gene transcription, controlling RNA stability, and other processes [16,50–53].
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These events underlie the role of ATM and ATR signaling in viral replication demonstrated for
herpesviruses [54,55], papillomaviruses [56,57], and polyomaviruses [58,59]. Here, our data indicate
that ATM and ATR signaling is an important host factor involved in HBV replication, specifically in
triggering HBV reactivation. The molecular mechanism(s) of the pro-viral activity of ATM and ATR
signaling for HBV as well as for the other viruses have yet to be elucidated.
In the era of direct-acting antivirals, HBV reactivation can be successfully managed in clinical
practice [60,61]. Still, it can be a severe and often fatal complication in patients with an overt or occult
HBV infection or HBV-associated cancer. HBV reactivation depends on many factors, such as the
immune status of patients [5], HBV mutations [62], co-infection with other viruses [63], and/or additional
therapies as the ones administered to patients with HBV-associated cancer [5,6,64]. Our finding that
HBV replication and HBV reactivation may be induced by transcriptional activation of ATM and ATR
(ATM-ATR signaling) in response to DNA damage, points to the necessity of carefully choosing drugs
administered to HBV-infected patients to avoid ones with DNA-damaging activity.
To conclude, HBV replication is tightly connected to DDR, namely ATM and ATR signaling.
Activation of the latter by DNA-damaging agents may drive HBV reactivation. Further analysis of
DDR signaling at the protein level and testing of known drugs and novel compounds for the capacity
to suppress ATM/ATR signaling and concomitant HBV replication are urgently needed.
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